| Zacks Company Profile for Spyre Therapeutics, Inc. (SYRE : NSDQ) |
|
|
| |
| • Company Description |
| Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based in WALTHAM, Mass.
Number of Employees: 65 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $15.96 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 628,426 shares |
| Shares Outstanding: 60.28 (millions) |
| Market Capitalization: $962.00 (millions) |
| Beta: 2.68 |
| 52 Week High: $40.26 |
| 52 Week Low: $10.91 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-9.88% |
-13.26% |
| 12 Week |
25.97% |
5.95% |
| Year To Date |
-31.44% |
-35.80% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
221 CRESCENT STREET BUILDING 23 SUITE 105
-
WALTHAM,MA 02453
USA |
ph: 617-651-5940
fax: 512-872-5121 |
eric.mcintyre@spyre.com |
http://www.spyre.com |
|
|
| |
| • General Corporate Information |
Officers
Cameron Turtle - Chief Executive Officer; President and Director
Jeffrey W. Albers - Chairman of the Board
Scott Burrows - Chief Financial Officer
Peter Harwin - Director
Tomas Kiselak - Director
|
|
Peer Information
Spyre Therapeutics, Inc. (CORR.)
Spyre Therapeutics, Inc. (RSPI)
Spyre Therapeutics, Inc. (CGXP)
Spyre Therapeutics, Inc. (BGEN)
Spyre Therapeutics, Inc. (GTBP)
Spyre Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00773J202
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 60.28
Most Recent Split Date: 9.00 (0.04:1)
Beta: 2.68
Market Capitalization: $962.00 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.75 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.99 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
